Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32634603
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Int+J+Antimicrob+Agents
2020 ; 56
(2
): 106080
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the
novel coronavirus (SARS-CoV-2)
#MMPMID32634603
Song Y
; Zhang M
; Yin L
; Wang K
; Zhou Y
; Zhou M
; Lu Y
Int J Antimicrob Agents
2020[Aug]; 56
(2
): 106080
PMID32634603
show ga
Currently, there is no approved therapy for coronavirus disease 2019 (COVID-19).
The World Health Organization (WHO) therefore endorses supportive care only.
However, frontline clinicians and researchers have been experimenting with
several virus-based and host-based therapeutics since the outbreak of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China. China's National
Health Commission has issued the first COVID-19 treatment guidelines with therapy
suggestions, which has inspired clinical studies worldwide. This review evaluates
the major therapeutics. Key evidence from in vitro research, animal models and
clinical research in emerging coronaviruses is examined. The antiviral therapies
remdesivir, lopinavir/ritonavir and umifenovir, if considered, should be
initiated before the peak of viral replication for an optimal outcome. Ribavirin
may be beneficial as an add-on therapy but is ineffective as monotherapy.
Corticosteroid use should be limited to specific co-morbidities. Intravenous
immunoglobulin (IVIg) is not recommended owing to lack of data in COVID-19. The
traditional Chinese medicine Xuebijing may benefit patients with complications of
bacterial pneumonia or sepsis. The efficacy of interferon is unclear owing to
conflicting outcomes in coronavirus studies. Chloroquine and hydroxychloroquine
have shown in vitro inhibition of SARS-CoV-2, but studies on their clinical
efficacy and whether the benefits outweigh the risk of dysrhythmias remain
inconclusive. For patients who develop cytokine release syndrome, interleukin-6
inhibitors may be beneficial.